Trial Profile

A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 [Agatolimod] In Patients With Stage Iv Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Agatolimod (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Jan 2009 Official title updated from ClinicalTrials.gov record. Actual end date reported as September 2004; actual patient number is 42.
20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
07 Aug 2006 Status change

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com